MA46568A - Dosage biologique de formulations d'insuline - Google Patents

Dosage biologique de formulations d'insuline

Info

Publication number
MA46568A
MA46568A MA046568A MA46568A MA46568A MA 46568 A MA46568 A MA 46568A MA 046568 A MA046568 A MA 046568A MA 46568 A MA46568 A MA 46568A MA 46568 A MA46568 A MA 46568A
Authority
MA
Morocco
Prior art keywords
insulin formulations
biological dosage
dosage
biological
insulin
Prior art date
Application number
MA046568A
Other languages
English (en)
Inventor
Jan Amstrup
Thomas Åskov Pedersen
Louise Hjerrild Zeuthen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA46568A publication Critical patent/MA46568A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA046568A 2016-10-24 2017-10-24 Dosage biologique de formulations d'insuline MA46568A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16195387 2016-10-24

Publications (1)

Publication Number Publication Date
MA46568A true MA46568A (fr) 2019-08-28

Family

ID=57208127

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046568A MA46568A (fr) 2016-10-24 2017-10-24 Dosage biologique de formulations d'insuline

Country Status (6)

Country Link
US (1) US10914728B2 (fr)
EP (1) EP3529615A1 (fr)
JP (1) JP7022746B2 (fr)
CN (1) CN109891237B (fr)
MA (1) MA46568A (fr)
WO (1) WO2018077851A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3853246A4 (fr) * 2018-09-21 2023-01-11 Case Western Reserve University Analogues d'insuline à chaîne unique de site 2

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990013540A1 (fr) 1989-04-19 1990-11-15 Enzon, Inc. Carbonates actifs d'oxydes de polyalkylene pour la modification de polypeptides
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO1997022360A2 (fr) 1995-12-20 1997-06-26 Medical Research Council Regulation de synthese de proteines et procede de criblage pour agents pharmaceutiques
GB0007915D0 (en) 2000-03-31 2000-05-17 Univ Bristol Protein kinase assay
WO2003087761A2 (fr) 2002-04-05 2003-10-23 Cell Signaling Technology, Inc. Profilage de molecules d'une maladie et reponse therapeutique utilisant des anticorps phospho-specifiques
JP2005528921A (ja) 2002-06-10 2005-09-29 メタボレックス インコーポレーティッド Ｃｘ３ｃｒ１修飾物質を用いる糖尿病の治療および診断の方法
US7220539B1 (en) 2002-06-12 2007-05-22 The Salk Institute For Biological Studies Protein kinase B/Akt modulators and methods for the use thereof
US20050014682A1 (en) * 2003-07-16 2005-01-20 Mike Mueckler Cell-free assay for insulin signaling
GB0328157D0 (en) 2003-12-04 2004-01-07 Imp College Innovations Ltd Compounds
EP1898931B1 (fr) 2005-07-07 2014-12-31 Postech Foundation Modulateur de captage du glucose et procede de traitement du diabete et des complications du diabete
EP2404934A1 (fr) * 2006-09-22 2012-01-11 Novo Nordisk A/S Analogues d'insuline résistants à la protéase
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
CA2763749A1 (fr) 2009-06-05 2010-12-09 Mcmaster University Synthese et utilisation d'analogues d'insuline radiomarques
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
PL2773331T3 (pl) 2011-10-31 2016-08-31 Xeris Pharmaceuticals Inc Preparaty do leczenia cukrzycy
US9867869B2 (en) 2012-12-12 2018-01-16 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
CA2942524A1 (fr) 2013-03-15 2014-09-18 Case Western Reserve University Analogues d'insuline de site 2
CN105392475A (zh) 2013-07-24 2016-03-09 诺和诺德股份有限公司 包含片剂核和阴离子共聚物涂层的用于口服胰岛素给药的药学组合物
SG10201809457YA (en) * 2014-11-21 2018-11-29 Merck Sharp & Dohme Insulin receptor partial agonists

Also Published As

Publication number Publication date
US10914728B2 (en) 2021-02-09
JP2020502489A (ja) 2020-01-23
WO2018077851A1 (fr) 2018-05-03
JP7022746B2 (ja) 2022-02-18
EP3529615A1 (fr) 2019-08-28
US20190361007A1 (en) 2019-11-28
CN109891237A (zh) 2019-06-14
CN109891237B (zh) 2022-08-23

Similar Documents

Publication Publication Date Title
PL3717471T3 (pl) Nowe związki i zawierające je kompozycje farmaceutyczne do leczenia chorób
EP3431075C0 (fr) Forme galénique d'édaravone
MA49116A (fr) Compositions pharmaceutiques contenant de l'insuline
EP3325668A4 (fr) Édition de l'adn mitochondrial
UY36056A (es) “compuestos de heteroarilo o arilo bicíclicos fusionados “.
LT3479819T (lt) Stabilus skystas vaistinis preparatas
EP3618840C0 (fr) Formulations d'insuline stables
EP3673899C0 (fr) Formulation de poudre nasale pour le traitement de l'hypoglycémie
HUE071155T2 (hu) Biszkolin-tetratiomolibdát Wilson-kór kezelésére
EP4289478C0 (fr) Composition pharmaceutique d'edaravone
EP3618723A4 (fr) Cathéter d'imagerie
PL3424499T3 (pl) Kompozycja farmaceutyczna do leczenia bólu neuropatycznego
IL263997A (en) Human-enzyme mediated depletion of cystine
EP3648739A4 (fr) Composition d'injection cutanée
EP3682016A4 (fr) Formulations pour l'administration de composés
DK3403674T3 (da) Farmaceutiske sammensætninger til behandling af smerte
EP3313380A4 (fr) Composition pour l'administration d'agents actifs à un animal
MA45158A (fr) Composition pharmaceutique comprenant de l'éteplirsen
EP3454658A4 (fr) Formulations de glyphosate contenant des tensioactifs d'amidoalkylamine
EP3429581A4 (fr) Formulations d'énalapril
MA45727A (fr) Analogues de l'insuline
FR3029193B1 (fr) Micro-station d'epuration biologique
EP3416672A4 (fr) Formulations d'oritavancine
EP3397269A4 (fr) Formulations stables de peptide de glucagon
DK3419628T3 (da) Medikament til behandling af diabetiske fodinfektioner